Freeline Therapeutics Holdings is a clinical-stage, systemic adeno-associated virus-based gene therapy company. Co.'s pipeline includes programs in the clinic and late-stage preclinical product candidates, as well as research programs targeting applications for systemic gene therapy. Co.'s product candidate, verbrinacogene setparvovec (FLT180a) is intended for the treatment of patients in whom a deficiency of functional clotting Factor IX, causes moderate or severe hemophilia B. Co. is also developing FLT190 for the treatment of Fabry disease, as well as FLT201 and FLT210, for the treatment of Gaucher disease and hemophilia A, respectively. The FRLN average annual return since 2020 is shown above.
The Average Annual Return on the FRLN average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether FRLN average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FRLN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|